Cue Biopharma Announces Board Changes and Officer Compensation Updates
Ticker: CUE · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1645460
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Cue Biopharma's board is shaking up, with new directors coming in and exec pay getting adjusted.
AI Summary
On November 17, 2025, Cue Biopharma, Inc. reported a change in its board of directors, with the election of new directors and the departure of existing ones. The company also announced updates regarding compensatory arrangements for its officers. Specific details on the individuals involved and the financial implications of these arrangements were not fully disclosed in this initial filing.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- November 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 473324577 (identifier) — IRS Employer Identification No.
- 40 Guest Street Boston , Massachusetts 02135 (address) — Address of principal executive offices
- 617-949-2680 (phone_number) — Registrant's telephone number
FAQ
Who are the new directors elected to the Cue Biopharma, Inc. board?
The filing indicates the election of new directors but does not name them in the provided text.
Which directors have departed from the Cue Biopharma, Inc. board?
The filing states the departure of directors but does not specify their names in the provided text.
What specific changes were made to the compensatory arrangements of Cue Biopharma, Inc.'s officers?
The filing mentions updates to compensatory arrangements but does not detail the specifics in the provided text.
What is the effective date of the reported board and officer changes for Cue Biopharma, Inc.?
The earliest event reported is November 17, 2025.
What is the primary business of Cue Biopharma, Inc. according to the filing?
Cue Biopharma, Inc. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2025-11-20 16:00:24
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
- $556,837 — severance payment in an amount equal to $556,837.60, less all applicable taxes and withh
Filing Documents
- cue-20251117.htm (8-K) — 65KB
- 0001193125-25-289713.txt ( ) — 192KB
- cue-20251117.xsd (EX-101.SCH) — 44KB
- cue-20251117_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 17, 2025, Cue Biopharma, Inc. (the "Company") and Matteo Levisetti, Chief Medical Officer, agreed that Dr. Levisetti's employment with the Company will terminate effective November 28, 2025 (the "Separation Date"). In connection with his departure, Dr. Levisetti is entitled, subject to his execution and nonrevocation of a separation and release of claims agreement, to severance benefits substantially consistent with those previously disclosed severance benefits set forth in Dr. Levisetti's employment agreement payable in connection with a termination without cause, including (i) a lump sum cash severance payment in an amount equal to $556,837.60, less all applicable taxes and withholdings, which represents (a) nine months of Dr. Levisetti's base salary, plus (b) a prorated portion of his target 2025 annual bonus, based on the number of days that he is employed in 2025 through the Separation Date, such lump sum payable in the Company's first regular payroll cycle that follows the effective date of the separation and release of claims agreement; and (ii) if Dr. Levisetti is eligible for and timely elects to continue receiving group health insurance coverage under COBRA, continued payment by the Company of the full premiums for such coverage commencing on the Separation Date and continuing until the earliest of (a) nine months following the Separation Date, (b) the date Dr. Levisetti obtains new employment that offers health and/or dental insurance that is reasonably comparable to that offered by the Company and (c) the date COBRA continuation coverage would otherwise terminate in accordance with the provisions of COBRA.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: November 20, 2025 By: /s/ Usman Azam Name: Usman Azam Title: President and Chief Executive Officer